Dr. Jones received an Honorary Lifetime Fellowship at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) on August 29, 2017 in Montreal, Canada
Friedrichsdorf, GERMANY / Fairfax, VA, USA, August 30, 2017: The PharmaLex Group, a leading specialist provider of Development Consulting, Regulatory Affairs, Quality Management & Compliance Services, as well as Pharmacovigilance, is pleased to announce that the International Society for Pharmacoepidemiology (ISPE) honored Judith K. Jones, MD, PhD, Founder of The Degge Group, Ltd., a PharmaLex company, at a special event on August 29, 2017, during the 33rd ICPE.
ISPE honors individuals with special accomplishments in the field of Pharmacoepidemiology. This award is only given in exceptional circumstances, with only two Honorary Lifetime Fellowships having been bestowed to date. Dr. Jones joins an elite group, receiving her award for her lifetime productivity in the field and for her pioneering role in the Society. She has been a member of ICPE since its inception 33 years ago. During this time, she has led ISPE as a Fellow, past President, former member of Board of Directors, Vice President Finance, keynote speaker, member of Special Interest Groups, workshop teacher, session chair, co-author for ISPE-sponsored publications, and coined the modern term “medical products epidemiology”.
“It is a great honor to receive such as prestigious award from ISPE” said Dr. Jones, Founder of The Degge Group, Ltd. “I have spent many years working in the field of pharmacoepidemiology, so to be honored by such a significant organization is truly humbling”, she added. Dr. Thomas Dobmeyer, CEO PharmaLex, explained, “We are delighted for Judith. This award is testament to her significant contribution to pharmacoepidemiology.” “Judith has undertaken pioneering work. Passing her knowledge and insights on to her team of subject matter experts makes her expertise accessible to the entire pharmaceutical industry”, Dr. Tilo Netzer, CEO PharmaLex continued.
The PharmaLex Group now has over 650 employees, with 25 offices in 14 countries and more than 600 satisfied clients worldwide.
About PharmaLex <Confidence beyond compliance>:
Development Consulting, Regulatory Affairs, Quality Management & Compliance as well as Pharmacovigilance – are our core service areas. Whether you are looking for maintenance activities covering entire portfolios or are interested in bench-to-market guidance during product development and beyond, our worldwide teams are available when and where you need them. Our working models can be tailored to fit client needs to consistently deliver milestone achievements and exceed expectations. Our extensive experience covers all major therapeutic areas and most product categories beyond the traditional medicinal products, including advanced therapy medicinal products, orphan drugs, biosimilars and medical devices.
For further information, please contact:
Ms. Eva Keck
PharmaLex GmbH; Director Business Development Operations
+49 621 18 15 38 0
Harrlachweg 6; 68163 Mannheim